Exagen Inc (XGN)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $105.37M
Last updated: Nov 17, 2026 at 11:06 AM ET
Exagen Inc (XGN) Competitors
The companies most similar to Exagen are Insight Molecular Diagnostics (IMDX), Precipio (PRPO) and Veracyte (VCYT). By market cap, Exagen ranks 9th of the 13 companies on this page; IDEXX Laboratories (IDXX) is the largest at $55.48B. The median P/E of the 5 companies with a P/E is 26.8x.
Peer Comparison
XGN's ROIC of -40.4% is below the peer median of 5.8%, and its revenue growth of 6.8% is above the median of 6.2%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| Exagen (XGN) | $105.37M | N/A | 1.3x | -25.1% | -40.4% | 6.8% | 0.00% |
| Insight Molecular Diagnostics Inc. (IMDX) | $70.03M | N/A | 40.9x | 0.0% | 197.8% | -53.9% | 0.00% |
| Precipio Inc (PRPO) | $39.68M | N/A | 1.3x | -4.1% | -5.7% | 8.3% | 0.00% |
| Veracyte Inc (VCYT) | $1.96B | 13.3x | 3.3x | 21.8% | 8.2% | 15.1% | 0.00% |
| IDEXX Laboratories Inc (IDXX) | $55.48B | 47.3x | 11.8x | 25.4% | 44.3% | 9.9% | 0.00% |
| Atrium Therapeutics, Inc. Common Stock (RNA) | $162.00M | N/A | 3.3x | -180.9% | -44.5% | 24.2% | 0.00% |
| Revvity Inc. (RVTY) | $17.24B | 26.8x | 5.6x | 8.6% | 3.4% | 4.3% | 0.19% |
| IQVIA Holdings Inc (IQV) | $43.69B | 22.0x | 2.5x | 8.1% | 8.5% | 8.0% | 0.00% |
| Myriad Genetics Inc (MYGN) | $542.92M | N/A | 0.7x | -16.1% | -29.5% | -1.5% | 0.00% |
| Adaptive Biotechnologies Corp (ADPT) | $4.70B | N/A | 15.0x | -23.7% | N/A | -10.7% | 0.00% |
| Anixa Biosciences Inc (ANIX) | $91.08M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Agilent Technologies Inc (A) | $49.05B | 28.5x | 6.6x | 19.5% | 13.1% | 8.1% | 0.59% |
| MDxHealth SA (MDXH) | $13.75M | N/A | N/A | -38.3% | -40.5% | -17.2% | 0.00% |
| Peer median | $1.25B | 26.8x | 4.5x | 0.0% | 5.8% | 6.2% | 0.00% |
Similar Companies
These are the 12 companies most similar to Exagen, ranked by how closely their business, size, sector and industry match. The largest group, 10 of the 12, is in Diagnostics & Research; the other 2 are in Biotechnology.
| Company | About | Peers |
|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX)Diagnostics & Research | OncoCyte Corporation is a precision diagnostics company in the United States and internationally. The company is headquartered in Irvine, California. | IMDX competitors |
| Precipio Inc (PRPO)Diagnostics & Research | Precipio, Inc., a cancer diagnostic and reagent technology company, provides diagnostic products and services in the United States oncology market. | PRPO competitors |
| Veracyte Inc (VCYT)Diagnostics & Research | Veracyte, Inc. is a genomic diagnostics company in the United States and internationally. The company is headquartered in South San Francisco, California. | VCYT competitors |
| IDEXX Laboratories Inc (IDXX)Diagnostics & Research | IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture... | IDXX competitors |
| Atrium Therapeutics, Inc. Common Stock (RNA)Biotechnology | Avidity Biosciences, Inc., a biopharmaceutical company, is dedicated to the development of oligonucleotide-based therapies. | RNA competitors |
| Revvity Inc. (RVTY)Diagnostics & Research | Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets globally. | RVTY competitors |
| IQVIA Holdings Inc (IQV)Diagnostics & Research | IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology... | IQV competitors |
| Myriad Genetics Inc (MYGN)Diagnostics & Research | Myriad Genetics, Inc., a molecular diagnostics company, develops and markets predictive, personalized... | MYGN competitors |
| Adaptive Biotechnologies Corp (ADPT)Diagnostics & Research | Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. | ADPT competitors |
| Anixa Biosciences Inc (ANIX)Biotechnology | Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. | ANIX competitors |
| Agilent Technologies Inc (A)Diagnostics & Research | Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets... | A competitors |
| MDxHealth SA (MDXH)Diagnostics & Research | MDxHealth SA is a prominent biotechnology company focused on precision diagnostics that enhance cancer management, particularly in prostate and bladder cancers. | MDXH competitors |
Frequently Asked Questions About XGN
Who are Exagen's main competitors?
The companies most similar to Exagen include Insight Molecular Diagnostics (IMDX), Precipio (PRPO), Veracyte (VCYT), IDEXX Laboratories (IDXX) and Atrium Therapeutics, Inc. Common Stock (RNA), listed from the closest match.
Who is Exagen's biggest competitor?
IDEXX Laboratories (IDXX) is the largest of the similar companies at $55.48B; Insight Molecular Diagnostics (IMDX) is the closest match by business profile, size, sector and industry.
How does XGN stock compare with its competitors?
XGN's P/S is 1.3x against a peer median of 4.5x; its net margin is -25.1% against a peer median of 0.0%.
Which of Exagen's competitors pays a higher dividend?
Exagen pays no dividend. Agilent Technologies (A) and Revvity (RVTY) have higher forward dividend yields; Agilent Technologies (A) has the highest at 0.59%.
Is Exagen bigger than its competitors?
No. Exagen is 9th by market cap among the 13 companies on this page; the largest is IDEXX Laboratories (IDXX) at $55.48B.
XGN pages: Overview, Earnings, Forecast, Financials, Competitors